These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30769245)

  • 21. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
    Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
    MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
    Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
    Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Events supposedly attributable to vaccination or immunization during pandemic influenza A (H1N1) vaccination campaigns in Latin America and the Caribbean.
    Ropero-Álvarez AM; Whittembury A; Bravo-Alcántara P; Kurtis HJ; Danovaro-Holliday MC; Velandia-González M
    Vaccine; 2015 Jan; 33(1):187-92. PubMed ID: 25444798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-licensure surveillance of quadrivalent inactivated influenza (IIV4) vaccine in the United States, Vaccine Adverse Event Reporting System (VAERS), July 1, 2013-May 31, 2015.
    Haber P; Moro PL; Lewis P; Woo EJ; Jankosky C; Cano M
    Vaccine; 2016 May; 34(22):2507-12. PubMed ID: 27015735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Passive enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Belgium, Germany and Spain, an observational study: protocol for the 2018/2019 influenza season.
    Dos Santos G; Yeakey A; Shende V; Smith K; Lin F; Zandman-van-Dijk E; Damaso S; Schmidt A
    BMJ Open; 2019 Aug; 9(8):e028043. PubMed ID: 31427321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010.
    Vellozzi C; Broder KR; Haber P; Guh A; Nguyen M; Cano M; Lewis P; McNeil MM; Bryant M; Singleton J; Martin D; DeStefano F
    Vaccine; 2010 Oct; 28(45):7248-55. PubMed ID: 20850534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea.
    Choe YJ; Cho H; Song KM; Kim JH; Han OP; Kwon YH; Bae GR; Lee HJ; Lee JK
    Jpn J Infect Dis; 2011; 64(4):297-303. PubMed ID: 21788704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia.
    Pillsbury AJ; Glover C; Jacoby P; Quinn HE; Fathima P; Cashman P; Leeb A; Blyth CC; Gold MS; Snelling T; Macartney KK
    BMJ Open; 2018 Oct; 8(10):e023263. PubMed ID: 30341132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid online identification of adverse events after influenza immunization in children by PCIRN's National Ambulatory Network.
    Bettinger JA; Vanderkooi OG; MacDonald J; Kellner JD
    Pediatr Infect Dis J; 2014 Oct; 33(10):1060-4. PubMed ID: 25361187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation.
    Regan AK; Blyth CC; Tracey L; Mak DB; Richmond PC; Effler PV
    Vaccine; 2015 Jul; 33(31):3689-94. PubMed ID: 26079616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Italian post-marketing surveillance for adverse event reports after MF59-adjuvanted H1N1v vaccination.
    Parretta E; Ianniello B; Ferrazin F; Rossi F; Capuano A
    Vaccine; 2011 May; 29(20):3708-13. PubMed ID: 21406267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced passive surveillance of influenza vaccination in England, 2016-2017- an observational study using an adverse events reporting card.
    de Lusignan S; Ferreira F; Damaso S; Byford R; Pathirannehelage S; Yeakey A; Yonova I; Schuind A; Dos Santos G
    Hum Vaccin Immunother; 2019; 15(5):1048-1059. PubMed ID: 30648923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges in implementing yearly enhanced safety surveillance of influenza vaccination in Europe: lessons learned and future perspectives.
    Dos Santos G
    Hum Vaccin Immunother; 2019; 15(11):2624-2636. PubMed ID: 31116631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia.
    Regan AK; Tracey L; Gibbs R
    Vaccine; 2015 Nov; 33(46):6149-51. PubMed ID: 26476362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse events following immunization (AEFI) with the novel influenza a (H1N1) 2009 vaccine: findings from the national registry of all vaccine recipients and AEFI and the passive surveillance system in South Korea.
    Kim JH; Cho HY; Hennessey KA; Lee HJ; Bae GR; Kim HC
    Jpn J Infect Dis; 2012; 65(2):99-104. PubMed ID: 22446114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementing near real-time vaccine safety surveillance using the Clinical Practice Research Datalink (CPRD).
    Leite A; Thomas SL; Andrews NJ
    Vaccine; 2017 Dec; 35(49 Pt B):6885-6892. PubMed ID: 29056424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report from enhanced safety surveillance of two influenza vaccines (Vaxigrip and Intanza 15 μg) in two European countries during influenza season 2016/17 and comparison with 2015/16 season.
    Chabanon AL; Bricout H; Ballandras C; Souverain A; Caroe TD; Butler KM
    Hum Vaccin Immunother; 2018 Feb; 14(2):378-385. PubMed ID: 29148911
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Study on surveillance data of adverse events following immunization of seasonal influenza vaccine in China during 2015-2018 influenza season].
    Wu WD; Li KL; Xu DS; Ye JK; Xiao QY; Wang HQ
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):987-992. PubMed ID: 31607043
    [No Abstract]   [Full Text] [Related]  

  • 39. Surveillance systems and methods for monitoring the post-marketing safety of influenza vaccines at the Centers for Disease Control and Prevention.
    Moro PL; Li R; Haber P; Weintraub E; Cano M
    Expert Opin Drug Saf; 2016 Sep; 15(9):1175-83. PubMed ID: 27268157
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, immunogenicity, and safety evaluation of an MF59-adjuvanted quadrivalent influenza virus vaccine compared with non-adjuvanted influenza vaccine in children: a multicentre, randomised controlled, observer-blinded, phase 3 trial.
    Vesikari T; Kirstein J; Devota Go G; Leav B; Ruzycky ME; Isakov L; de Bruijn M; Oberye J; Heijnen E
    Lancet Respir Med; 2018 May; 6(5):345-356. PubMed ID: 29631857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.